# MEI Pharma Inc. (MEIP)

Source: https://www.quantisnow.com/company/MEIP
Generated: 2026-11-06T21:28:46.869Z

- Ticker: MEIP
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2003
- Website: meipharma.com

## About

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.

## Latest MEIP news and filings

- 2025-09-15 20:00 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-unregistered-sales-of-6200807)
- 2025-09-10 20:40 UTC [SEC Form 3] [New insider Schornstein Alexander claimed ownership of 4,365,472 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-schornstein-alexander-claimed-ownership-of-4365472-shares-sec-6196751)
- 2025-09-10 13:00 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-amendments-to-articles-6196104)
- 2025-09-10 13:00 UTC [MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker 'LITS'](https://www.quantisnow.com/insight/mei-pharma-inc-rebrands-as-lite-strategy-inc-adopts-new-6196070)
- 2025-09-08 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by MEI Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-mei-pharma-inc-6192321)
- 2025-09-05 20:36 UTC [SEC Form 424B3] [SEC Form 424B3 filed by MEI Pharma Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-mei-pharma-inc-6191871)
- 2025-09-04 20:31 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-entry-into-a-6190316)
- 2025-08-26 21:21 UTC [SEC Form S-3] [Amendment: SEC Form S-3/A filed by MEI Pharma Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-3a-filed-by-mei-pharma-inc-6179579)
- 2025-08-20 21:56 UTC [SEC Form 4] [SEC Form 4 filed by Director Riezman Joshua](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-riezman-joshua-6173975)
- 2025-08-20 21:54 UTC [SEC Form 3] [SEC Form 3 filed by new insider Riezman Joshua](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-riezman-joshua-6173971)
- 2025-08-06 20:43 UTC [SEC Form S-3] [SEC Form S-3 filed by MEI Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-mei-pharma-inc-6151211)
- 2025-08-06 20:05 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-leadership-update-6150366)
- 2025-08-05 12:05 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-regulation-fd-disclosure-6146448)
- 2025-08-05 12:00 UTC [Mergers & Acquisitions] [MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising](https://www.quantisnow.com/insight/mei-pharma-acquires-litecoin-launches-100m-institutional-treasury-strategy-with-6146390)
- 2025-07-30 20:40 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-unregistered-sales-of-6139045)
- 2025-07-30 20:18 UTC [SEC Form 3] [New insider Lee Charles Benjamin claimed ownership of 292,397 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-lee-charles-benjamin-claimed-ownership-of-292397-shares-6138792)
- 2025-07-23 20:34 UTC [SEC Form 424B5] [SEC Form 424B5 filed by MEI Pharma Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-mei-pharma-inc-6129993)
- 2025-07-22 21:22 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Leadership Update, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-entry-into-a-6128626)
- 2025-07-22 20:35 UTC [Public Offering] [MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange](https://www.quantisnow.com/insight/mei-pharma-announces-closing-of-100000000-private-placement-to-initiate-6128470)
- 2025-07-18 12:30 UTC [MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange](https://www.quantisnow.com/insight/mei-pharma-announces-100000000-private-placement-to-initiate-litecoin-treasury-6125012)
- 2025-07-18 01:40 UTC [SEC Form 4] [SEC Form 4 filed by Director Wood Steven D](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-wood-steven-d-6124806)
- 2025-07-18 01:39 UTC [SEC Form 4] [SEC Form 4 filed by Director Reynolds Thomas C](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-reynolds-thomas-c-6124805)
- 2025-07-18 01:38 UTC [SEC Form 4] [SEC Form 4 filed by Director Glover Nicholas](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-glover-nicholas-6124804)
- 2025-07-18 01:36 UTC [SEC Form 4] [SEC Form 4 filed by Director Flynn James P](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-flynn-james-p-6124803)
- 2025-07-18 01:36 UTC [SEC Form 4] [SEC Form 4 filed by Secretary, Acting CEO & CFO File Justin J.](https://www.quantisnow.com/insight/sec-form-4-filed-by-secretary-acting-ceo-cfo-file-6124802)
- 2025-07-18 01:33 UTC [SEC Form 4] [SEC Form 4 filed by Director Driscoll Frederick W](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-driscoll-frederick-w-6124800)
- 2025-05-13 20:05 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-results-of-operations-6035782)
- 2025-05-13 20:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by MEI Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-mei-pharma-inc-6035663)
- 2025-03-07 21:30 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-leadership-update-financial-5933664)
- 2025-02-12 21:12 UTC [Dividends] [MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position](https://www.quantisnow.com/insight/mei-pharma-reports-second-quarter-fiscal-year-2025-cash-position-5884647)
- 2025-02-12 21:05 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-results-of-operations-5884524)
- 2025-02-12 21:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by MEI Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-mei-pharma-inc-5884411)
- 2025-01-31 21:30 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-submission-of-matters-5865422)
- 2024-12-20 22:15 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by MEI Pharma Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-mei-pharma-inc-5822649)
- 2024-12-20 22:10 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by MEI Pharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-mei-pharma-inc-5822625)
- 2024-11-25 21:30 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Shareholder Director Nominations](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-shareholder-director-nominations-5790378)
- 2024-11-14 21:10 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-results-of-operations-5775792)
- 2024-11-12 21:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by MEI Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-mei-pharma-inc-5767446)
- 2024-11-12 21:05 UTC [Dividends] [MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position](https://www.quantisnow.com/insight/mei-pharma-reports-first-quarter-fiscal-year-2025-cash-position-5767344)
- 2024-10-25 20:05 UTC [SEC Form 8-K] [MEI Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits](https://www.quantisnow.com/insight/mei-pharma-inc-filed-sec-form-8-k-entry-into-a-5738584)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/MEIP
- Earnings history: https://www.quantisnow.com/earnings/MEIP
- Dividend history: https://www.quantisnow.com/dividends/MEIP
- Insider transactions: https://www.quantisnow.com/insiders/MEIP
- Options chain: https://www.quantisnow.com/options/MEIP
- SEC 8-K filings only: https://www.quantisnow.com/company/MEIP/8-k
- RSS and alerts for MEIP: https://www.quantisnow.com/docs/rss-feeds.md